+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report

  • PDF Icon

    Report

  • 214 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5029843

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach $278 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$153 Million in the year 2022, is projected to reach a revised size of US$278 Million by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. Collagen, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $49.5 Million, While China is Forecast to Grow at 9.8% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$49.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 7.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 28 Featured) -

  • Anika Therapeutics, Inc.
  • Arthro Kinetics AG
  • B. Braun Melsungen AG
  • BioTissue SA
  • CartiHeal, Inc.
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Smith & Nephew PLC
  • Zimmer Biomet Holdings, Inc.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Frequently Asked Questions about the Autologous Matrix-Induced Chondrogenesis (AMIC) Market

What is the estimated value of the Autologous Matrix-Induced Chondrogenesis (AMIC) Market?

The Autologous Matrix-Induced Chondrogenesis (AMIC) Market was estimated to be valued at $153 Million in 2022.

What is the growth rate of the Autologous Matrix-Induced Chondrogenesis (AMIC) Market?

The growth rate of the Autologous Matrix-Induced Chondrogenesis (AMIC) Market is 7.8%, with an estimated value of $278 Million by 2030.

What is the forecasted size of the Autologous Matrix-Induced Chondrogenesis (AMIC) Market?

The Autologous Matrix-Induced Chondrogenesis (AMIC) Market is estimated to be worth $278 Million by 2030.

Who are the key companies in the Autologous Matrix-Induced Chondrogenesis (AMIC) Market?

Key companies in the Autologous Matrix-Induced Chondrogenesis (AMIC) Market include Anika Therapeutics, Inc., Arthro Kinetics AG, B. Braun Melsungen AG, BioTissue SA, CartiHeal, Inc., Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew PLC and Zimmer Biomet Holdings, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Increasing Prevalence of Joint Disorders to Fuel Growth in Autologous Matrix-Induced Chondrogenesis Market
  • Autologous Matrix-Induced Chondrogenesis (AMIC): A Prelude
  • Global Economic Update
  • Exhibit 1: Although Declining for the First Time Since the Russia-Ukraine War, Global Oil Prices Still Remains Higher Than 2019 Levels Which In Turn Will Take Inflation Longer Than Expected to Fall: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
  • Exhibit 2: Slower Than Anticipated Decline Makes Inflation a Stickier Than Expected Problem to Solve in 2023: Global Inflation Rates (In %) for the Years 2019 through 2024
  • Exhibit 3: Global Economy Slowly Limps Towards Recovery, Resiliently Navigating the War & Decades-High Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
  • Pandemic Casts Shadow over Normalcy of Orthopedic Surgery Volumes
  • Exhibit 4: Elective Orthopedic Surgical Procedures Conducted in the US: April-June 2020 Vs April-June 2019
  • Competition
  • Exhibit 5: Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • INFLUENCER/PRODUCT/TECHNOLOGY INSIGHTS
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • AMIC Holds Significance in Cartilage Repair Domain
  • Rise in Sports Participation and Increase in Sports-Related Injuries Augment Growth Prospects
  • Autologous Matrix-Induced Chondrogenesis (AMIC) in Ankle Repair: A Review
  • Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth
  • Rise in Incidence of Osteoporosis to Benefit Market Growth
  • Exhibit 6: Global Osteoporosis Prevalence: Number of People with Osteoporosis in Millions by Select Country/Region for 2012 and 2022
  • AMIC: Highly Effective in Management of Focal Chondral Defects of the Knee
  • Assessment of Open & Arthroscopic Approaches for AMIC to Repair Cartilage Defects
  • Cellular Therapy as Lifeblood of Clinical Routines Targeting Cartilage Regeneration
  • MACI Solutions: Promising Options in Articular Cartilage Treatment
  • Aging Population and their Vulnerability to Various Bone and Joint Related Diseases and Disorders Drive Healthy Market Growth
  • Exhibit 7: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Exhibit 8: Select Musculoskeletal Conditions - Percentage Breakdown by Age Group
  • Rise in Overweight Patients to Boost Prospects
  • Exhibit 9: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
  • Exhibit 10: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
  • Changing Lifestyle Impacting Bone Health
  • Rising Healthcare Spending Augurs Well for the Market
  • Exhibit 11: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Autologous Matrix-Induced Chondrogenesis (AMIC) Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 3: World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 4: World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2017, 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 7: World 13-Year Perspective for Collagen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 10: World 13-Year Perspective for Hyaluronic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 13: World 13-Year Perspective for Polyethylene Glycol (PEG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 16: World 13-Year Perspective for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 19: World 13-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Market Analytics
  • Table 20: USA Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 22: USA 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 25: Canada 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
JAPAN
  • Table 26: Japan Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 28: Japan 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
CHINA
  • Table 29: China Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 30: China Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 31: China 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
EUROPE
  • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Market Analytics
  • Table 32: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 34: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2017, 2023 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 37: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
FRANCE
  • Table 38: France Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: France Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 40: France 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
GERMANY
  • Table 41: Germany Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 43: Germany 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 46: Italy 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
UNITED KINGDOM
  • Table 47: UK Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: UK Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 49: UK 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Spain Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 52: Spain 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: Russia Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 55: Russia 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 57: Rest of Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 58: Rest of Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
ASIA-PACIFIC
  • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Market Analytics
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 61: Asia-Pacific 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
LATIN AMERICA
  • Table 62: Latin America Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: Latin America Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 64: Latin America 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
REST OF WORLD
  • Table 65: Rest of World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 66: Rest of World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2021 and % CAGR
  • Table 67: Rest of World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Anika Therapeutics, Inc.
  • Arthro Kinetics AG
  • B. Braun Melsungen AG
  • BioTissue SA
  • CartiHeal, Inc.
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Smith & Nephew PLC
  • Zimmer Biomet Holdings, Inc.